{"id":"6836e767-e9db-4e94-905b-6e9b259463c5","slug":"ekso-indego-fda-510k","filingNumber":null,"filingType":"fda_510k","jurisdiction":"us_fda","applicantCompanyId":"c36c0cb6-a327-458b-94ec-288386588250","filingDate":"2016-01-01T00:00:00.000Z","decisionDate":"2016-01-01T00:00:00.000Z","status":"cleared","clearanceScope":"FDA 510(k) clearance for Ekso Indego Personal. For SCI levels T3 to L5 in community or home settings.","sources":[{"url":"https://www.stocktitan.net/sec-filings/EKSO/10-k-ekso-bionics-holdings-inc-files-annual-report-1b783c257ad0.html","title":"Ekso Bionics 10-K","sourceName":"SEC"}],"verificationPosture":"verified","capFlagNotes":null,"relatedIncidentId":null,"reviewStatus":"unreviewed","deprecatedAt":null,"deprecationReason":null,"createdAt":"2026-07-15T02:29:33.135Z","updatedAt":"2026-07-15T02:29:33.135Z","applicantCompany":{"id":"c36c0cb6-a327-458b-94ec-288386588250","slug":"ekso-bionics","name":"Ekso Bionics"},"modelLinks":[{"id":"38cadb8e-5ec8-4409-93f6-ec815c065808","modelId":"3e6569fb-d5de-40f1-986c-b9ddf2c43aa5","regulatoryFilingId":"6836e767-e9db-4e94-905b-6e9b259463c5","createdAt":"2026-07-15T02:29:34.004Z","model":{"slug":"ekso-indego","modelName":"Ekso Indego Personal/Therapy"}},{"id":"e465c4d0-f1c6-49f4-bb86-432f5b73d074","modelId":"894204d2-44c2-4f9e-9261-5d64481f866a","regulatoryFilingId":"6836e767-e9db-4e94-905b-6e9b259463c5","createdAt":"2026-07-15T02:29:34.871Z","model":{"slug":"parker-indego","modelName":"Indego"}}]}